CN118804750A - 含有特力利汀的颗粒和包含该颗粒的制剂 - Google Patents

含有特力利汀的颗粒和包含该颗粒的制剂 Download PDF

Info

Publication number
CN118804750A
CN118804750A CN202480000782.0A CN202480000782A CN118804750A CN 118804750 A CN118804750 A CN 118804750A CN 202480000782 A CN202480000782 A CN 202480000782A CN 118804750 A CN118804750 A CN 118804750A
Authority
CN
China
Prior art keywords
telithromycin
acid
granules
granules containing
silica
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202480000782.0A
Other languages
English (en)
Chinese (zh)
Inventor
西村卓朗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sawai Pharmaceutical Co Ltd
Original Assignee
Sawai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sawai Pharmaceutical Co Ltd filed Critical Sawai Pharmaceutical Co Ltd
Priority claimed from PCT/JP2024/001234 external-priority patent/WO2024171708A1/ja
Publication of CN118804750A publication Critical patent/CN118804750A/zh
Pending legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN202480000782.0A 2023-02-13 2024-01-18 含有特力利汀的颗粒和包含该颗粒的制剂 Pending CN118804750A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2023-020036 2023-02-13
JP2023020036 2023-02-13
PCT/JP2024/001234 WO2024171708A1 (ja) 2023-02-13 2024-01-18 テネリグリプチン含有粒子及びそれを含む製剤

Publications (1)

Publication Number Publication Date
CN118804750A true CN118804750A (zh) 2024-10-18

Family

ID=91895935

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202480000782.0A Pending CN118804750A (zh) 2023-02-13 2024-01-18 含有特力利汀的颗粒和包含该颗粒的制剂

Country Status (2)

Country Link
JP (1) JP7518316B1 (https=)
CN (1) CN118804750A (https=)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020070260A (ja) * 2018-10-31 2020-05-07 沢井製薬株式会社 テネリグリプチン含有医薬組成物、テネリグリプチン含有医薬組成物の製造方法、テネリグリプチン含有錠剤及びテネリグリプチン含有錠剤の製造方法
JP2021161096A (ja) * 2020-04-03 2021-10-11 金剛化学株式会社 テネリグリプチン塩のアモルファス形態及びその製造方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023056991A (ja) * 2021-10-08 2023-04-20 日本ジェネリック株式会社 テネリグリプチン含有医薬組成物
JP2023156269A (ja) * 2022-04-12 2023-10-24 日本ジェネリック株式会社 テネリグリプチン含有医薬組成物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020070260A (ja) * 2018-10-31 2020-05-07 沢井製薬株式会社 テネリグリプチン含有医薬組成物、テネリグリプチン含有医薬組成物の製造方法、テネリグリプチン含有錠剤及びテネリグリプチン含有錠剤の製造方法
JP2021161096A (ja) * 2020-04-03 2021-10-11 金剛化学株式会社 テネリグリプチン塩のアモルファス形態及びその製造方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
WENQI WU等: "Organic acids as co-formers for co-amorphous systems – Influence of variation in molar ratio on the physicochemical properties of the co-amorphous systems", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, vol. 131, 31 October 2018 (2018-10-31), pages 25 *
上田广: "共非晶质：Co-amorphous的研究动向：难水溶性药物的经口制剂化技术最前线", 31 December 2016, CMC出版株式会社, pages: 118 *
中本敬三: "製剤中における医薬品化合物の結晶・非晶質状態の評価", 药剂学, vol. 75, no. 3, 31 December 2015 (2015-12-31), pages 147 *
竹内洋文: "多孔性微粒子载体的药物固体分散体粒子设计", 粉体工学会志, vol. 40, no. 3, 31 December 2003 (2003-12-31), pages 157 - 162 *

Also Published As

Publication number Publication date
JPWO2024171708A1 (https=) 2024-08-22
JP7518316B1 (ja) 2024-07-17

Similar Documents

Publication Publication Date Title
US8877238B2 (en) Film-coated tablet or granules containing as active ingredient a pyridylpyrimidine compound or a pharmaceutically acceptable salt of this compound
EP1008354B1 (en) Immediately disintegrable medicinal compositions
EP2938362B1 (en) Dry granulation process for producing tablet compositions of metformin and compositions thereof
EP3417861B1 (en) Pharmaceutical composition containing jak kinase inhibitor or pharmaceutically acceptable salt thereof
KR101632079B1 (ko) 디히드로피리딘 칼슘 채널 길항제를 함유하는 약제학적 조성물 및 그것의 제조방법
SI23290A (sl) Nove oblike ivabradin hidroklorida
US20100120815A1 (en) Stable solid preparation containing 4,5-epoxymorphinan derivative
EP4147689A1 (en) Lenvatinib formulation
JP6639024B2 (ja) 化学的な安定性を改善した、非晶質体ソリフェナシン含有製剤
US10583087B2 (en) Pharmaceutical composition for oral administration
EP2295040B1 (en) Pharmaceutical compositions of pramipexole
US7959948B2 (en) Pharmaceutical composition of quetiapine fumarate
EP2101742B1 (en) Pharmaceutical composition containing clopidogrel hydrogenesulphate of polymorph 1 form
CN118804750A (zh) 含有特力利汀的颗粒和包含该颗粒的制剂
JP7799904B2 (ja) テネリグリプチン含有製剤
WO2024171708A1 (ja) テネリグリプチン含有粒子及びそれを含む製剤
EP2903593B1 (en) Tablet containing composite with cyclodextrin
JP2018177789A (ja) コハク酸ソリフェナシン含有固形医薬組成物
WO2022119543A1 (en) A process for tablet formulations comprising amorphous dapagliflozin and metformin hydrochloride
CN114053421A (zh) 一种血小板生成素受体激动剂的组合物及其制备方法
EP4302755B1 (en) Palbociclib formulation containing an amino acid
RU2847537C1 (ru) Фармацевтические композиции, содержащие производное диаминопиримидина или его фармацевтически приемлемую соль, и способы их приготовления
CN116133649A (zh) 包含二氨基嘧啶衍生物或其药学上可接受的盐的药物组合物及其制备方法
EP4321154A1 (en) A tablet of tolvaptan and at least one binder processed with spray granulation
KR20180003340A (ko) 무정형 솔리페나신 함유 경구용 고형제제 및 그 제조방법

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination